What is the recommended dose of domperidone (galactagogue) for a breastfeeding woman?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Domperidone Dosing for Breastfeeding

The recommended dose of domperidone for increasing breast milk production is 10 mg orally three times daily (30 mg/day total), which can be increased to 20 mg three times daily (60 mg/day total) if the lower dose is insufficient. 1, 2

Standard Dosing Protocol

Initial Dose

  • Start with 10 mg orally three times daily (30 mg/day total) for mothers experiencing lactation failure despite non-pharmacological interventions 1, 3, 4
  • This lower dose should be maintained for at least 14 days to assess efficacy 3, 5

Dose Escalation

  • If milk production remains inadequate, increase to 20 mg three times daily (60 mg/day total) 2
  • The higher dose (20 mg TID) produces a clinically significant increase in milk production compared to 10 mg TID, though the difference may not reach statistical significance 2

Duration of Treatment

  • Continue treatment for 4 weeks at the therapeutic dose 2
  • After 4 weeks, taper the frequency to twice daily for 1 week, then once daily for 1 additional week before discontinuation 2
  • Some protocols use 14-28 days of continuous treatment before tapering 3, 5

Clinical Context and Timing

When to Initiate

  • Domperidone should only be started after optimizing non-pharmacological interventions including frequent feeding/pumping, proper latch technique, adequate maternal hydration and nutrition 6
  • Approximately 72% of mothers with perceived lactation failure can increase milk production with counseling alone, so pharmacological treatment should be reserved for true lactation failure 3
  • Domperidone can be initiated as early as the first week postpartum if lactation failure is documented 7

Expected Efficacy

  • Mothers receiving 20 mg TID (60 mg/day) increased milk production from baseline of 156 mL to 401 mL after 14 days 3
  • 77.8% of mothers achieve a 50% or greater increase in milk volume when domperidone is started within 21 days postpartum 5
  • The medication works by antagonizing dopamine and elevating prolactin levels, with prolactin levels increasing significantly by day 7 of treatment 3

Safety Considerations and Side Effects

Common Adverse Effects

  • Side effects occur in approximately 48% of women and appear to be dose-related 7
  • Most common side effects include weight gain (25%), headaches (17%), and dry mouth (13%) 7
  • Higher doses (>60 mg/day) are associated with 73% incidence of side effects compared to 38% at doses ≤30 mg/day 7
  • Approximately 9% of women discontinue domperidone due to side effects 7

Compatibility with Breastfeeding

  • Domperidone is compatible with breastfeeding and is listed as a safe anti-emetic option for breastfeeding women 1
  • Mothers should have access to a breast pump if any delay in infant feeding occurs, as domperidone may increase milk supply before the infant can effectively remove it 6

Important Caveats

Regulatory Status

  • Domperidone is not FDA-approved in the United States for use as a galactagogue, though it is widely used internationally for this indication 6
  • Metoclopramide (maximum 30 mg/day) is the FDA-approved alternative in the United States, though domperidone is more commonly utilized globally 6

Dosing Variability in Practice

  • Real-world surveys show wide variation in dosing, with some women using doses as high as 160 mg/day, though this exceeds evidence-based recommendations 7
  • Doses above 60 mg/day are associated with significantly higher side effect rates without clear evidence of additional benefit 7

Target Population

  • Domperidone is particularly beneficial for mothers of preterm infants (≤31 weeks gestation) who are at highest risk of lactation failure 4, 5
  • 95% of infants whose mothers received domperidone were exclusively breastfeeding at hospital discharge compared to 52.4% in the placebo group 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

The effect of two different domperidone doses on maternal milk production.

Journal of human lactation : official journal of International Lactation Consultant Association, 2013

Research

Effect of Domperidone on Breast Milk Production in Mothers of Sick Neonates: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 2021

Research

Enhancing Human Milk Production With Domperidone in Mothers of Preterm Infants.

Journal of human lactation : official journal of International Lactation Consultant Association, 2017

Guideline

Metoclopramide for Lactation Enhancement

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.